JPH01279838A - Lysozyme chloride-containing plaster for gingivitis and pyorrhea - Google Patents
Lysozyme chloride-containing plaster for gingivitis and pyorrheaInfo
- Publication number
- JPH01279838A JPH01279838A JP63108053A JP10805388A JPH01279838A JP H01279838 A JPH01279838 A JP H01279838A JP 63108053 A JP63108053 A JP 63108053A JP 10805388 A JP10805388 A JP 10805388A JP H01279838 A JPH01279838 A JP H01279838A
- Authority
- JP
- Japan
- Prior art keywords
- film
- parts
- weight
- lysozyme chloride
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title claims abstract description 58
- 102000016943 Muramidase Human genes 0.000 title claims abstract description 54
- 108010014251 Muramidase Proteins 0.000 title claims abstract description 54
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims abstract description 54
- 239000004325 lysozyme Substances 0.000 title claims abstract description 54
- 229960000274 lysozyme Drugs 0.000 title claims abstract description 54
- 235000010335 lysozyme Nutrition 0.000 title claims abstract description 54
- 208000007565 gingivitis Diseases 0.000 title claims abstract description 17
- 201000001245 periodontitis Diseases 0.000 title claims abstract description 16
- 239000011505 plaster Substances 0.000 title abstract 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 38
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 19
- 229960000458 allantoin Drugs 0.000 claims abstract description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 9
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 4
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930007845 β-thujaplicin Natural products 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- -1 tesitdesitin Chemical compound 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 235000019477 peppermint oil Nutrition 0.000 claims description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 3
- 229920000569 Gum karaya Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 241000934878 Sterculia Species 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000010494 karaya gum Nutrition 0.000 claims description 3
- 239000000231 karaya gum Substances 0.000 claims description 3
- 229940039371 karaya gum Drugs 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000005844 Thymol Substances 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 claims description 2
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 claims description 2
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 claims description 2
- 229960001378 dequalinium chloride Drugs 0.000 claims description 2
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 claims description 2
- 229940045574 dibucaine hydrochloride Drugs 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003720 enoxolone Drugs 0.000 claims description 2
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 2
- 229960001907 nitrofurazone Drugs 0.000 claims description 2
- WGVIBWRLLMUUAJ-UHFFFAOYSA-N o-[2-(diethylamino)ethyl] 4-amino-2-hexoxybenzenecarbothioate Chemical compound CCCCCCOC1=CC(N)=CC=C1C(=S)OCCN(CC)CC WGVIBWRLLMUUAJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229940079841 sodium copper chlorophyllin Drugs 0.000 claims description 2
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229960000790 thymol Drugs 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract description 5
- 230000002439 hemostatic effect Effects 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 206010030113 Oedema Diseases 0.000 abstract description 2
- 235000010418 carrageenan Nutrition 0.000 abstract description 2
- 229920001525 carrageenan Polymers 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 208000010266 Aggressive Periodontitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 108010025899 gelatin film Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 201000006727 periodontosis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000010408 film Substances 0.000 description 144
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 239000012790 adhesive layer Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000010410 layer Substances 0.000 description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000001070 adhesive effect Effects 0.000 description 10
- 229960003511 macrogol Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000007721 medicinal effect Effects 0.000 description 5
- 208000028169 periodontal disease Diseases 0.000 description 5
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 5
- 229920001800 Shellac Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000004208 shellac Substances 0.000 description 4
- 229940113147 shellac Drugs 0.000 description 4
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 4
- 235000013874 shellac Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000001420 bacteriolytic effect Effects 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920003112 high viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は塩化リゾチームを含有した水溶性フィルムを口
腔内の＠１部に直接貼付することにより歯肉炎・歯槽膿
漏に伴う諸症状を緩和し、快方に導く塩化リゾチーム含
有歯肉炎・歯Ｗ！膿漏用貼イ＝Ｊ剤に関するものである
。Detailed Description of the Invention (Industrial Application Field) The present invention alleviates various symptoms associated with gingivitis and alveolar pyorrhea by applying a water-soluble film containing lysozyme chloride directly to the oral cavity. Gingivitis and teeth containing lysozyme chloride that leads to recovery! This is related to Pyorrhoea patch (J).
（従来の技術）
従来、歯肉炎・歯槽Ｉ！漏等の歯周疾店の治療に用いら
れた薬剤としては、患部に塗布しマツｉナージを行なう
軟膏、紬薬、クリームと、口腔内に定置して溶解させる
バッカル錠がある。(Conventional technology) Conventionally, gingivitis/alveolar I! Medications used for the treatment of periodontal diseases such as leakage include ointments, pongee medicines, and creams that are applied to the affected area for pine treatment, and buccal tablets that are placed in the oral cavity and dissolved.
しかしながら、軟膏、１ｍ２、クリームのような剤形で
は短時間のうちに唾液や体温等によって溶解し易いため
、口腔内に分散されたり飲み込まれたりすることが多く
、長時間の薬効が期待できない。また１回の塗布間がま
ちまちであるため一定量の投与が困難である。However, dosage forms such as ointments, 1 m2, and creams are easily dissolved by saliva, body temperature, etc. in a short period of time, and are often dispersed in the oral cavity or swallowed, so that long-term medicinal effects cannot be expected. Furthermore, since the time between applications varies, it is difficult to administer a constant amount.
これに対して、バッカル錠は錠剤であるので薬効の維持
、川沿の特定の問題を改善し得るが、口腔内前庭に於て
溶解させる使用方法のため、患部に的確に作用させるこ
とが難しく、確実な薬効を期待できない場合がある。ま
た、１ｊｍ１強の厚さがあるため口腔内に置くとき違和
感を生じて使用しずらいという問題もある。On the other hand, since buccal tablets are tablets, they can maintain medicinal efficacy and improve specific problems in the riverside, but because they are used by dissolving them in the vestibule of the oral cavity, it is difficult to apply them accurately to the affected area. Certain medicinal effects may not be expected. In addition, since it has a thickness of just over 1 m1, it feels uncomfortable when placed in the oral cavity, making it difficult to use.
（技術的課題）
そこで本発明者らは鋭意研究を重ね、どのような剤形が
この種の用途には最適であるかを検討したところ、外部
から見えにくい位置に患部があることから比較的広い面
積をカバーできること、患部へ付着し、容易に剥落しな
いこと、敏感な箇所であるため可能な限り違和感をおぼ
えない形態、性状であることなどが必要であるとの結論
に達した。この条件をみたすものはフィルム状の貼付剤
である。(Technical Issue) Therefore, the present inventors conducted extensive research and considered what kind of dosage form would be optimal for this type of use.As the affected area is located in a position that is difficult to see from the outside, the present inventors found that it is relatively difficult to see from the outside. We came to the conclusion that it was necessary to cover a wide area, to adhere to the affected area and not fall off easily, and to have a form and property that would cause as little discomfort as possible since the area is sensitive. A film-like adhesive patch satisfies this condition.
またフィルム状貼付剤に含有させる薬剤としては溶菌作
用、止血作用及び強力な消炎作用を有し、特に歯周疾患
の予防、運行阻止に効果を発揮する必要があり、そうし
たものの中では塩化リゾチームが最適である。塩化リゾ
チームは、ムコ多糖類分解酵素であり、細菌に対する溶
菌作用、カラゲニン浮腫等に対する消炎作用、その他、
組１１ｒ１復作用、止血作用等を有するｌｌＩ値ある消
炎酵素剤である。In addition, the drugs contained in the film patch must have bacteriolytic, hemostatic, and strong anti-inflammatory effects, and must be particularly effective in preventing periodontal disease and inhibiting periodontal disease. Among these, lysozyme chloride is Optimal. Lysozyme chloride is a mucopolysaccharide degrading enzyme, and has a lytic effect on bacteria, an anti-inflammatory effect on carrageenin edema, etc.
It is an anti-inflammatory enzyme agent with IIII value and has group 11r1 reaction, hemostasis, etc.
したがって、本発明の目的は塩化リゾチームを含有する
フィルム状の貼付剤であって、かつそのフィルムは少な
くとも水溶性フィルムであり、溶けながら塩化リゾチー
ムの患部への作用を発揮させる徐放性の塩化リゾチーム
含有歯肉炎・歯槽膿漏用貼付剤を提供することにある。Therefore, the object of the present invention is to provide a film-like patch containing lysozyme chloride, the film being at least a water-soluble film, and a sustained-release lysozyme chloride that exerts its effect on the affected area while being dissolved. An object of the present invention is to provide a patch for containing gingivitis and alveolar pyorrhea.
（技術的手段）
前記目的を達する本発明の要旨は、塩化リゾチームを水
溶性フィルム中に含有することを必須不可欠の要件とす
る塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤である
。(Technical means) The gist of the present invention that achieves the above object is a patch for gingivitis and alveolar pyorrhea containing lysozyme chloride, which has an essential requirement of containing lysozyme chloride in a water-soluble film.
歯肉炎・歯槽膿漏治療又は補助に用いられる、アラント
イン、ヒノキチオール、ハツカ油、酢酸トコフェロール
、カミツレチンキ、塩化セチルピリジニウム、塩酸クロ
ルヘキシジン、アミノ安息香酸エチル、塩酸ジブカイン
、塩酸ヘキソチオカイン、塩化デカリニウム、グリチル
レチン酸、グリチルリチン酸ジカリウム、チモール、塩
化ベンザルコニウム、サリチル酸ジフェンヒドラミン、
ニトロフラゾン、テシットデシチン、エデト酸ナトリウ
ム・カルシウム、フェノール、銅クロロフィリンナトリ
ウム、塩化ナトリウムから選ばれた１種又は２種以上を
塩化リゾチームとともに含有させ使用することもできる
。このうち特にアラントインは、湿地に生ずる多年性植
物の地下茎根を砕いて得た汁などに多く含まれており、
壊死組織（または錆層）を除去（剥離）する作用がある
と同時に、悪い歯周組織から新しい正常な組織への回復
を助長する薬効を発揮する。Allantoin, hinokitiol, peppermint oil, tocopherol acetate, chamomile tincture, cetylpyridinium chloride, chlorhexidine hydrochloride, ethyl aminobenzoate, dibucaine hydrochloride, hexothiocaine hydrochloride, dequalinium chloride, glycyrrhetinic acid, used for gingivitis/alveolar pyorrhea treatment or aid. Dipotassium glycyrrhizinate, thymol, benzalkonium chloride, diphenhydramine salicylate,
One or more selected from nitrofurazone, tesitdesitin, sodium/calcium edetate, phenol, sodium copper chlorophyllin, and sodium chloride may also be used together with lysozyme chloride. Among these, allantoin in particular is found in large amounts in the juice obtained by crushing the underground rhizomes of perennial plants that grow in wetlands.
It has the effect of removing (exfoliating) necrotic tissue (or rust layer), and at the same time has medicinal effects that promote the recovery of bad periodontal tissue to new, normal tissue.
本発明の構成によれば、塩化リゾチーム、或いは塩化リ
ゾチームとアラントイン等の有効成分は水溶性フィルム
中に均一に混合、分散させることが必須不可欠であり、
同フィルムに塗布若しくは埋設させただけでは本発明の
目的は達成できない。According to the structure of the present invention, it is essential that the active ingredients such as lysozyme chloride or lysozyme chloride and allantoin are uniformly mixed and dispersed in the water-soluble film.
The object of the present invention cannot be achieved simply by coating or embedding the film.
前記水溶性フィルムは主に口腔内から胃内で溶けるもの
を指称するが、本発明で水溶性フィルムという場合は腸
溶性フィルムも含めるものとする、前者としては、ポリ
ビニルピロリドン、ゼラチン、ポリビニルアルコール、
ポリアクリル酸ナトリウム、カルボキシメチルセルロー
ス
サンタンガム、カラヤガム、アルギン酸ナトリウム、メ
チルセルロース、カルボキシビニルポリマー、カンテン
及び、ヒドロキシプロピルセルロースに構成する。The water-soluble film mainly refers to those that dissolve in the oral cavity and stomach, but in the present invention, the term water-soluble film also includes enteric-coated films.The former includes polyvinylpyrrolidone, gelatin, polyvinyl alcohol,
Consists of sodium polyacrylate, carboxymethylcellulose santhanum gum, karaya gum, sodium alginate, methylcellulose, carboxyvinyl polymer, agar, and hydroxypropylcellulose.
また腸溶性フィルムとしてはヒドロキシブロピルメチル
セルロースアセテートザクシネート、ヒドロキシプロピ
ルメチルセルロースフタレート、酢酸フタル酸セルロー
ス、カルボキシメチルエチルセルロース、及びメタアク
リル酸アクリル酸エチルコポリマーが使用できるが、こ
れらは口腔内の粘ｌＩ層に接着するのを防止するもので
ある。In addition, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, carboxymethylethylcellulose, and methacrylic acid ethyl acrylate copolymer can be used as enteric films; This prevents it from adhering to the surface.
このように水溶性フィルムは可食性ないし水溶性である
ことが必要であるが、それだ【ノでは十分でなく製剤と
して厚くならない構造でなければならない。具体的には
水溶性フィルムの溶解速度と薬効の持続及び違和感等と
のかね合いからその厚さを決定する。即ち、薄過ぎると
フィルム剤にもよるが早く溶けすぎるので２０μｍ以上
が良い。−方最大厚さは個人差があるけれども、製剤状
態で３００μｍ以下が好ましく、それ以上になると大多
数の者が違和感を覚えるようになる。As described above, the water-soluble film needs to be edible or water-soluble, but this is not sufficient, and the film must have a structure that does not become thick as a preparation. Specifically, the thickness of the water-soluble film is determined based on the balance between the dissolution rate of the water-soluble film, the duration of its medicinal efficacy, and discomfort. That is, if it is too thin, it will dissolve too quickly, although it depends on the film material, so the thickness is preferably 20 μm or more. Although the maximum thickness varies from person to person, it is preferably 300 μm or less in the form of a formulation, and if it exceeds that, most people will feel uncomfortable.
塩化リゾチーム、或いは塩化リゾチームとアラントイン
、その他の有効成分を薄いフィルム中に均一に含有させ
かつ剤厚を制御するには、前記成分及び薄層フィルムを
形成可能な物質を溶解、或いは混合分散せしめる溶媒の
選定もｆｆｉ要である。In order to uniformly contain lysozyme chloride, lysozyme chloride and allantoin, and other active ingredients in a thin film and control the thickness, a solvent is used to dissolve or mix and disperse the ingredients and a substance capable of forming a thin film. It is also necessary to select ffi.
この種の溶媒は、当該製剤が口腔内に使用され体内に入
ることから、人体に対して有害な作用を有するものであ
ってはならないのは当然である。Naturally, this type of solvent must not have any harmful effects on the human body since the preparation is used in the oral cavity and enters the body.
また、展延後溶媒を留去することから、ある程度比熱の
小さいもの、さらに、溶媒燵についても溶媒留去の点で
出来るだけ少ない吊で、必要な薬物量を溶解せしめる溶
媒でなければならない。Furthermore, since the solvent is distilled off after spreading, it is necessary to use a solvent with a relatively low specific heat, and also a solvent that can dissolve the required amount of drug with as little effort as possible in terms of solvent distillation.
以上の点を考慮した結果、当該貼付剤では溶剤を水、エ
タノール、塩化メチレンに限定し、その上で貼付剤を形
成するために必要な諸成分をも選定したもので、それに
よって剤Ｊ９を２０〜３００μｍとすることが可能にな
ったものである。As a result of considering the above points, the solvent for this patch was limited to water, ethanol, and methylene chloride, and the various ingredients necessary to form the patch were also selected, thereby making Agent J9. This makes it possible to set the thickness to 20 to 300 μm.
（発明の作用）
以上の如く構成された本発明の貼付剤において、塩化リ
ゾチーム或いは塩化リゾチームとアラン１−イン等の有
効成分は水溶性フィルム中に含有されているので、この
フィルムが口腔内で溶けるにしたがって、塩化リゾチー
ム等の有効成分もそれが貼付された口腔内患部に直接作
用する。特に本発明における水溶性フィルムはその全体
が貼付部分の形状に適応して口腔内粘膜に付着し、かつ
付着全面積において患部に直接薬効を発揮するので、バ
ッカル錠或いは、フィルムに薬物を埋設したり塗布した
ものに対して、的確に患部を抑えやすく、そうした構造
的特徴と相乗して患部に的確に薬効を及ぼすことができ
る。(Action of the Invention) In the patch of the present invention constructed as described above, the active ingredients such as lysozyme chloride or lysozyme chloride and allan-1-yne are contained in the water-soluble film, so that this film does not dissolve in the oral cavity. As it dissolves, the active ingredients such as lysozyme chloride also act directly on the affected area in the oral cavity to which it is applied. In particular, the water-soluble film of the present invention adapts to the shape of the application part as a whole and adheres to the oral mucosa, and exerts its medicinal effect directly on the affected area over the entire adhesion area. When applied, it is easy to suppress the affected area accurately, and in conjunction with these structural features, it is possible to accurately exert medicinal effects on the affected area.
（発明の効果）
このようにして塩化リゾチームを水溶性フィルムに含有
させたことにより、溶菌作用、止血作用及び強力な消炎
作用を呈して歯周疾患の予防、進行阻止に持続的に効果
を発揮し、さらにアラントイン等を併せて含有させたと
きは組織修復作用により正常組織の回復が促進されるの
で歯周疾患の治療効果をより一層高めることができる。(Effects of the invention) By incorporating lysozyme chloride into the water-soluble film in this way, it exhibits bacteriolytic, hemostatic, and strong anti-inflammatory effects, and is continuously effective in preventing and inhibiting the progression of periodontal disease. However, when allantoin and the like are further contained, the recovery of normal tissues is promoted by the tissue repair action, so that the therapeutic effect on periodontal diseases can be further enhanced.
（実施例）
次に本発明の実施例を示すが、本発明はこれに特定され
るものではない。(Example) Next, an example of the present invention will be shown, but the present invention is not limited to this.
第１図は、水溶性フィルムを接着層１と非接着層２から
なる２層の積層フィルムとした例である。FIG. 1 shows an example in which the water-soluble film is a two-layer laminated film consisting of an adhesive layer 1 and a non-adhesive layer 2.
その接着層は、ポリビニルビＯリドン、ゼラチン、ポリ
ビニルアルコール、ポリアクリル酸ナトリウム、カルボ
キシメチルセルロース、デンプン、キサンタンガム、カ
ラヤガム、アルギン酸ナトリウム、メチルセルロ−ス
から選ばれた１種又は２種以上からなる口腔内可溶性フ
ィルムとし、非接着層を、ヒドロキシプロピルメチルセ
ルロースアセテートサクシネート、ヒドロキシプロピル
メチルセルロースフタレート、酢酸フタル酸セルロース
、カルボキシメチルエチルセルロース、メタアクリル酸
アクリル酸エチルコポリマー等から選ばれた１種又は２
種以上からなる口腔内難溶性若しくは口腔内不溶性フィ
ルムとしている。The adhesive layer is an intraorally soluble film made of one or more selected from polyvinylbiolidone, gelatin, polyvinyl alcohol, sodium polyacrylate, carboxymethylcellulose, starch, xanthan gum, karaya gum, sodium alginate, and methylcellulose. and the non-adhesive layer is made of one or two selected from hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, carboxymethylethylcellulose, methacrylic acid ethyl acrylate copolymer, etc.
It is a film that is poorly soluble in the oral cavity or insoluble in the oral cavity.
塩化リゾチーム等の有効成分は接着層フィルム中に含有
しており、それにより、塩化リゾチームの外部への放出
を抑制し、接着層と接する歯肉炎・歯槽膿漏の患部から
の吸収効果を特に高めることを可能としている。Active ingredients such as lysozyme chloride are contained in the adhesive layer film, thereby suppressing the release of lysozyme chloride to the outside and particularly enhancing the absorption effect from affected areas of gingivitis and alveolar pyorrhea that are in contact with the adhesive layer. This makes it possible.
また、第２図は積層フィルムの接着層１を連発溶解性フ
ィルム１ａ、中間層を接着性のある遅発溶解性フィルム
１ｂ、非接着層２を口腔内不溶性若しくは口腔内難溶性
フィルムの３層とすることにより、連発溶解性フィルム
１ａにより初期接着性を高め、かつすみやかに塩化リゾ
チームの放出が行われるようにした例である。遅発溶解
性フィルム１ｂは、フィルムの溶解性をυ１＠し、塩化
リゾチーム放出の持続性を高めることができる。In addition, Fig. 2 shows three layers: the adhesive layer 1 of the laminated film is a rapidly dissolving film 1a, the intermediate layer is an adhesive slow dissolving film 1b, and the non-adhesive layer 2 is an oral insoluble film or an intraoral hardly soluble film. This is an example in which the continuous dissolving film 1a enhances the initial adhesion and promptly releases lysozyme chloride. The delayed dissolution film 1b can increase the solubility of the film υ1@ and increase the sustainability of lysozyme chloride release.
第３図、第４図、第５図、第６図は塩化リゾチームを各
種フィルム中に含有させた実施例１乃至１０のものに関
する溶出曲線を示す。これにより非接着層２である腸溶
性フィルムからの溶出率は、４時間経過時に於ても１０
％を越えることはなく、それに対し患部に対する塩化リ
ゾチームの溶出率は顕著であり、かつ徐放的に作用する
ことが理解される。なお、この溶出特性は塩化リゾチー
ムにのみ着目した場合であるが、これと併せてアラント
イン等を含有させた場合もそれら有効成分の溶出特性が
塩化リゾチームの場合と同様であることは明らかである
。FIGS. 3, 4, 5, and 6 show elution curves for Examples 1 to 10 in which lysozyme chloride was contained in various films. As a result, the dissolution rate from the enteric film, which is the non-adhesive layer 2, was 10 even after 4 hours.
It is understood that the dissolution rate of lysozyme chloride to the affected area is remarkable and that it acts in a sustained manner. Note that this elution characteristic is based only on lysozyme chloride, but it is clear that when allantoin and the like are also included, the elution characteristics of these active ingredients are the same as in the case of lysozyme chloride.
（実施例１）
腸溶性フィルム（非接＠層）；ヒドロキシプロピルメチ
ルセルロースアセテートサクシネート８５ｍｍ部、フィ
ルム補強剤としてセラツク３重琵部をエタノール・塩化
メチレン（１： １ ） ４００ｆｆｉ伍部に混合溶
解させ、また、可塑剤としてマクロゴール４００１０重
量部、春色剤として酸化チタン２重量部を水１００重量
部に混合溶解又は分散させ、前記溶液と均一混合し、展
延乾燥後厚さ約２０μｍの腸溶性フィルムを形成した。(Example 1) Enteric film (non-contact layer); 85 mm parts of hydroxypropyl methyl cellulose acetate succinate and 3 parts of shellac as a film reinforcing agent were mixed and dissolved in 400 ffi of ethanol/methylene chloride (1:1). In addition, 10 parts by weight of Macrogol 400 as a plasticizer and 2 parts by weight of titanium oxide as a spring coloring agent were mixed and dissolved or dispersed in 100 parts by weight of water, mixed uniformly with the solution, and after being spread and dried, an enteric coated material having a thickness of about 20 μm was obtained. A film was formed.
溶解性フィルム（接着層）；塩化リゾチーム５重間部、
マクロゴール４００１０重量部を水２００重量部に均−
混合又は溶解させ、また、ヒドロキシプロピルセルロー
ス（ＨＰＣ−Ｈ）３０重量部、ヒドロキシプロピルセル
ロース（ＨＰＣ−Ｌ）４５重量部、カルボキシビニルポ
リマー１０１糟部をエタノール１０００重機部に溶解さ
せ、前記溶液と均一混合し、腸溶性フィルム上に、展延
乾燥後厚さ約１００μｍの溶解性フィルムを形成した。Dissolvable film (adhesive layer); lysozyme chloride pentafold,
Evenly distribute 10 parts by weight of Macrogol 400 in 200 parts by weight of water.
Also, 30 parts by weight of hydroxypropyl cellulose (HPC-H), 45 parts by weight of hydroxypropyl cellulose (HPC-L), and 101 parts by weight of carboxyvinyl polymer were dissolved in 1000 parts by weight of ethanol, and the mixture was homogeneously mixed with the above solution. The mixture was mixed, spread and dried to form a soluble film with a thickness of about 100 μm on the enteric film.
以上の腸溶性フィルム（非接着ＩＩ）と、溶解性フィル
ム（接着層）により厚さ約１２０μｍの積層。The above enteric film (non-adhesive II) and soluble film (adhesive layer) are laminated to a thickness of about 120 μm.
（２層）フィルムを形成した。A (two-layer) film was formed.
（実施例２）
腸溶性フィルム（非接着Ｒ）；（実施例１）と同様の操
作により形成した。(Example 2) Enteric film (non-adhesive R): Formed by the same operation as in (Example 1).
溶解性フィルム（接着層）；塩化リゾチーム５１ｍ部、
マクロゴール４００１０重量部を水１００重１部に均−
混合又は溶解させ、またポリビニルピロリドン（ＰＶＰ
）５０重端部、ＨＰＣ−Ｈ１５重湯部、ＨＰＣ−Ｌ２０
重ｆｆｉ部をエタノール１０００重量部に混合溶解させ
、前記溶液と均一混合し、腸溶性フィルム上に、展延乾
燥後厚さ約１００μｍの溶解性フィルムを形成した。Dissolvable film (adhesive layer); 51 m parts of lysozyme chloride,
Evenly distribute 10 parts by weight of Macrogol 400 in 1 part by weight of 100 parts of water.
Mix or dissolve polyvinylpyrrolidone (PVP
)50 heavy end part, HPC-H15 heavy end part, HPC-L20
Parts of FFI were mixed and dissolved in 1000 parts by weight of ethanol, mixed uniformly with the solution, and after being spread and dried, a soluble film having a thickness of about 100 μm was formed on the enteric film.
以上の腸溶性フィルムと溶解性フィルムにより厚さ約１
２０μｍの２層の積層フィルムを形成した。The thickness of the enteric film and dissolvable film is approximately 1
A two-layer laminated film of 20 μm was formed.
（実施例３）
腸溶性フィルム（非接着層）；メタアクリル酸アクリル
酸エチルコポリマー９０重量部とマクロゴール４００１
０重両部を均一混合し、展延乾燥後厚さ約１０μｍの腸
溶性フィルムを形成した。(Example 3) Enteric film (non-adhesive layer): 90 parts by weight of methacrylic acid ethyl acrylate copolymer and Macrogol 4001
Both parts were uniformly mixed, spread and dried to form an enteric film with a thickness of about 10 μm.
溶解性フィルム（接着層）；塩化リゾデーム１０重酪部
、アラントイン５小聞部、マクロゴール４００１０ｆｆ
ｉｆｆｉ部、可塑剤としてグリセリン１０重吊部を水１
００重聞端金均−混合又は溶解させ、また、トＩＰＣ−
Ｈ５０重量部、１−ＩＰＣ−１１５重量部をエタノール
１０００重石部に混合溶解させ、前記溶液と均一混合し
、腸溶性フィルム上に、展延乾燥後厚さ約１５０μｍの
溶解性フィルムを形成した。Dissolvable film (adhesive layer): 10 parts of lysodeme chloride, 5 parts of allantoin, 10 parts of macrogol 400ff
iffi part, 10 parts of glycerin as a plasticizer and 1 part of water.
IPC-
50 parts by weight of H and 115 parts by weight of 1-IPC-1 were mixed and dissolved in 1000 parts by weight of ethanol and mixed uniformly with the above solution to form a soluble film having a thickness of about 150 μm after being spread and dried on the enteric film.
以上の腸溶性フィルムと、溶解性フィルムにより厚さ
１６０μｍの積層（υ１フィルムを形成した。Thickness due to enteric coated film and dissolvable film
A 160 μm lamination (υ1 film was formed).
（実施例４）
腸溶性フィルム（非接着層）；実施例３と同様の操作に
より形成した。(Example 4) Enteric film (non-adhesive layer); formed by the same operation as in Example 3.
溶解性フィルム（接着層）：塩化リゾチーム５重台部、
アラントイン５小聞部、マクロゴール４００１０ｍｍ部
を水１００重量部に均−混合又は溶解させ、またＰＶＰ
５０重聞部、端金ＩＰＣ−Ｈ１０重吊重吊１−ＩＰｃ−
Ｌ２０重聞端金エタノール１０００重量部に混合溶解さ
せ、前記溶液と均一混合し、腸溶性フィルム上に、展延
乾燥後厚さ約５０μｍの溶解性フィルムを形成した。Dissolvable film (adhesive layer): lysozyme chloride 5-layer base,
5 parts of allantoin and 10 mm parts of macrogol were uniformly mixed or dissolved in 100 parts by weight of water, and PVP
50 heavy lifting part, end metal IPC-H10 heavy lifting heavy lifting 1-IPc-
The mixture was mixed and dissolved in 1000 parts by weight of L20 heavy metal ethanol, mixed uniformly with the above solution, and after being spread and dried on an enteric film, a soluble film having a thickness of about 50 μm was formed.
以上の腸溶性フィルムと、溶解性フィルムにより厚さ約
６０μｍの積層（２層）フィルムを形成した。A laminated (two-layer) film having a thickness of approximately 60 μm was formed using the above enteric film and the soluble film.
（実施例５）
腸溶性フィルム（非接着層）；ヒドロキシプロピルメチ
ルセルロースアセテートサクシネート８５１吊部、セラ
ック３１聞部をエタノール・塩化メチレン（１：１）４
００重量部に混合溶解させ、また、マクロゴール４００
１０重型部、酸化チタン２重量部を水１００重量部に混
合溶解又は分散させ、前記溶液と均一混合し、展延乾燥
後厚さ約２０μｍの腸溶性フィルムを形成した。(Example 5) Enteric film (non-adhesive layer): Hydroxypropyl methyl cellulose acetate succinate 851 hanging part, shellac 31 part and ethanol/methylene chloride (1:1) 4
00 parts by weight, and also macrogol 400
10 parts by weight of titanium oxide and 2 parts by weight of titanium oxide were mixed and dissolved or dispersed in 100 parts by weight of water, mixed uniformly with the solution, and after being spread and dried, an enteric film having a thickness of about 20 μm was formed.
遅発溶解性フィルム（接着性を有する中間層）；塩化リ
ゾチーム５重量部、マクロゴール４００１０重量部を水
２００重Ｍ部に均−混合又は溶解させ、また、ＨＰＣ−
１−１３０重Ｍ部、トＩＰＣ−１４５重１部、カルボキ
シビニルポリマー１０重量部をエタノール１０００重量
部に混合溶解させ、前記溶液と均一混合し、腸溶性フィ
ルム上に、展延乾燥後厚さ約１００μｍの遅発溶解性フ
ィルムを形成した。Slow-dissolving film (intermediate layer with adhesive properties); 5 parts by weight of lysozyme chloride and 10 parts by weight of Macrogol 400 are uniformly mixed or dissolved in 200 parts by weight of water, and HPC-
1-130 parts by weight, 1 part by weight of IPC-145, and 10 parts by weight of carboxyvinyl polymer are mixed and dissolved in 1000 parts by weight of ethanol, mixed uniformly with the solution, spread on an enteric film, and after drying, the thickness is A slow dissolving film of approximately 100 μm was formed.
連発溶解性フィルム（接着層）；塩化リゾデーム５重量
部、マクロゴール４００１０重量部を水１００重量部に
均−混合又は溶解させ、また、ＰＶＰ５０同部、ＨＰ
Ｃ−８１５重量部、１−ＩＰｃ−１２０重量部をエタノ
ール１０００重量部に混合溶解させ、前記溶液と均一混
合し腸溶性フィルム上に展延された遅発溶解性フィルム
の上に、展延乾燥後厚さ約１００μｍの連発溶解性フィ
ルムを形成した。Rapidly soluble film (adhesive layer): 5 parts by weight of Lysodeme chloride and 10 parts by weight of Macrogol 400 are uniformly mixed or dissolved in 100 parts by weight of water, and the same parts of PVP and HP
15 parts by weight of C-8 and 120 parts by weight of 1-IPc-1 were mixed and dissolved in 1000 parts by weight of ethanol, mixed uniformly with the solution, spread on a slow dissolving film spread on an enteric film, and spread and dried. A continuously dissolvable film having a thickness of about 100 μm was then formed.
以上の腸溶性フィルムと遅発溶解性フィルム及び連発溶
解性フィルムにより厚さ約２２０μｍの積層（３層）フ
ィルムを形成した。A laminated (three-layer) film having a thickness of about 220 μm was formed from the above enteric film, slow dissolving film, and rapid dissolving film.
（実施例６）
腸溶性フィルム（非接着層）；メタアクリル酸アクリル
酸エチルコポリマー９０重間部とマクロゴール４００１
０重め部を均一混合し、展延乾燥後厚さ約１０μｍの腸
溶性フィルムを形成した。(Example 6) Enteric film (non-adhesive layer); methacrylic acid ethyl acrylate copolymer 90 polymer and macrogol 4001
The 0 weight portion was uniformly mixed, spread and dried to form an enteric film with a thickness of about 10 μm.
遅発溶解性フィルム（接着性を有する中間層）；塩化リ
ゾチーム１０重量部、アラシト１２５重聞部、マクロゴ
ール４００１０重量部、グリセリン１０重量部を水１０
０重湯部に均−混合又は溶解させ、またＨＰ Ｃ−Ｈ５
０重１部、ＨＰＣ−１１５重量部をエタノール１０００
重量部に混合溶解させ、前記溶液と均一混合し、腸溶性
フィルム上に、展延乾燥後厚さ約１５０μｍの遅発溶解
性フィルムを形成した。Slow dissolution film (intermediate layer with adhesive properties): 10 parts by weight of lysozyme chloride, 125 parts by weight of Aracito, 10 parts by weight of Macrogol 400, 10 parts by weight of glycerin, 10 parts by weight of water.
Evenly mixed or dissolved in 0 heavy hot water part, also HP C-H5
0 weight 1 part, HPC-115 weight part ethanol 1000
The mixture was mixed and dissolved in parts by weight, uniformly mixed with the above solution, and spread and dried to form a delayed dissolution film having a thickness of about 150 μm on an enteric film.
連発溶解性フィルム（接着層）：塩化リゾチーム５重量
部、アラントイン５重吊部、マクロゴール４００１０重
量部を水１００重量部に均−混合又は溶ｓさせ、マタ、
ＰＶＰ５０重１部、Ｎ Ｐ Ｃ−８１０重型部、ＮＰＣ
−１２０重聞都合エタノール１０００ｍｍ部に混合溶解
させ、前記溶液と均一混合し、腸溶性フィルム上に展延
された遅発溶解性フィルムの上に、展延乾燥後厚さ約５
０μｍの連発溶解性フィルムを形成した。Rapidly soluble film (adhesive layer): 5 parts by weight of lysozyme chloride, 5 parts of allantoin, and 10 parts by weight of Macrogol 400 are uniformly mixed or dissolved in 100 parts by weight of water.
PVP50 heavy 1 part, NPC-810 heavy part, NPC
- 120 ml of ethanol is mixed and dissolved in 1000 mm of ethanol, mixed uniformly with the above solution, and spread on a slow-dissolving film spread on an enteric film to a thickness of about 5 mm after drying.
A continuously dissolving film of 0 μm was formed.
以上の腸溶性フィルム、遅発溶解性フィルム及び連発溶
解性フィルムにより厚さ約２１０μｍの積層（３層）フ
ィルムを形成した。A laminated (three-layer) film with a thickness of about 210 μm was formed from the above enteric film, slow dissolving film, and rapid dissolving film.
（実施例７）
腸溶性フィルム（非接着層）：カルボキシメチルエチル
セルロース９０重置部、マクロゴール４００７重量部、
セラック３重重部をエタノール１０００重量部に均−混
合又は溶解させ、展延乾燥後厚さ約５μｍの腸溶性フィ
ルムを形成した。(Example 7) Enteric film (non-adhesive layer): 90 parts by weight of carboxymethylethyl cellulose, 4007 parts by weight of macrogol,
Three parts of shellac were uniformly mixed or dissolved in 1000 parts by weight of ethanol, and after being spread and dried, an enteric film having a thickness of about 5 μm was formed.
遅発溶解性フィルム（接着性を有する中間層）：塩化リ
ゾチーム１５重量部、アラントイン５重吊部、塩化ロゴ
ルピリジニウム２重量部を水１００重量部に均−混合又
は溶解さＶｌまた、ｌｌＰｃ−Ｈ６０重量部、ＨＰＣ−
１１０重量部、グリセリン８重量部をエタノール１００
０重量部に均−混合又は溶解させ、前記溶液と均一混合
し、腸溶解性フィルム上に、展延乾燥後厚さ約２００μ
ｍの遅発溶解性フィルムを形成した。Slow-dissolving film (intermediate layer with adhesive properties): 15 parts by weight of lysozyme chloride, 5 parts of allantoin, and 2 parts by weight of logolpyridinium chloride are homogeneously mixed or dissolved in 100 parts by weight of water. H60 parts by weight, HPC-
110 parts by weight, 8 parts by weight of glycerin, 100 parts by weight of ethanol
0 parts by weight, uniformly mixed with the above solution, spread and dried on an enteric film to a thickness of about 200 μm.
A slow dissolving film of m was formed.
連発溶解性フィルム（接着層）；塩化リゾチーム５重口
部、アラントイン５重量部、塩化セチルピリジニウム２
重量部を水１００重量部に均−混合又は溶解させ、また
、ＨＰＣ−１６０重吊重聞可塑剤としてプロピレングリ
コール２０重量部、グリセリン８重量部をエタノール１
０００１ｆｉ部に均−混合又は溶解させ、前記容液と均
一混合し、腸溶性フィルム上に展延された遅発溶解性フ
ィルム上に、展延乾燥後厚さ約５０μｍの連発溶解性フ
ィルムを形成した。Rapidly soluble film (adhesive layer): 5 parts by weight of lysozyme chloride, 5 parts by weight of allantoin, 2 parts by weight of cetylpyridinium chloride
Parts by weight were uniformly mixed or dissolved in 100 parts by weight of water, and 20 parts by weight of propylene glycol and 8 parts by weight of glycerin were mixed with 1 part by weight of ethanol as a plasticizer for HPC-160.
0001fi part, uniformly mixed with the above liquid, and after spreading and drying, a continuous dissolving film with a thickness of about 50 μm is formed on the slow dissolving film spread on the enteric film. did.
以上の腸溶性フィルム、遅発溶解性フィルム及び連発溶
解性フィルムにより厚さ約２５５μｍの積層（３層）フ
ィルムを形成した。A laminated (three-layer) film having a thickness of about 255 μm was formed from the above enteric film, slow dissolving film, and rapid dissolving film.
（実施例８）
腸溶性フィルム（非接着層）；ヒドロキシプロピルメチ
ルセルロースフタレート８５重量部、マクロゴール４０
０１３重量部、酸化チタン２重量部をエタノール・水（
８：２）３００重伍重邑均−混合又は溶解させ、展延乾
燥後厚さ約１０μｍの腸溶性フィルムを形成した。(Example 8) Enteric film (non-adhesive layer); 85 parts by weight of hydroxypropyl methylcellulose phthalate, macrogol 40
013 parts by weight and 2 parts by weight of titanium oxide were mixed with ethanol and water (
8:2) 300 tungsten and 300 yen were mixed or dissolved, and after being spread and dried, an enteric film with a thickness of about 10 μm was formed.
遅発溶解性フィルム（接着性を有する中間層）：塩化リ
ゾチーム５重量部、アラントイン５重間部、ハツカ油２
１聞部、塩化ナトリウム１０重量部を水１００１５１部
に均−混合又は溶解させ、また、ＨＰＣ−Ｈ３０重間部
、Ｉ」Ｐｃ−１３０重量部、カルボキシビニルポリマー
１０重量部、グリセリン８重量部をエタノール１０００
１伍部に均−混合又は溶解させ、前記溶液と均一混合し
、腸溶性フィルム上に展延乾燥後厚さ約３０μｍの連発
溶解性フィルムを形成した。Slow dissolution film (adhesive intermediate layer): 5 parts by weight of lysozyme chloride, 5 parts of allantoin, 2 parts of peppermint oil
1 part by weight, 10 parts by weight of sodium chloride was uniformly mixed or dissolved in 100,151 parts by weight of water, and 1 part by weight of HPC-H30, 130 parts by weight of I'Pc-1, 10 parts by weight of carboxyvinyl polymer, and 8 parts by weight of glycerin were added. ethanol 1000
The mixture was uniformly mixed or dissolved in one part, mixed uniformly with the above solution, and spread and dried on an enteric film to form a continuously dissolving film with a thickness of about 30 μm.
連発溶解性フィルム（接＠層）；塩化リゾチーム５重量
部、アラントイン５重量部、ハツカ油２重曾部、塩化ナ
トリウム１０重量部を水１００重量部に均−混合又は溶
解させ、ＰＶＰ４０重口部、ＨＰＣ−１２０重量部、グ
リセリン８重山部、マクロゴール４００１０重ａ部をエ
タノール１０００ 重１部に均−混合又は溶解させ、前
記溶液と均一混合し、腸溶性フィルム上に展延された遅
発溶解性フィルム上に、展延乾燥後厚さ約３０μｍの連
発溶解性フィルムを形成した。Repeated dissolution film (contact layer): 5 parts by weight of lysozyme chloride, 5 parts by weight of allantoin, 2 parts by weight of peppermint oil, and 10 parts by weight of sodium chloride were uniformly mixed or dissolved in 100 parts by weight of water, and 40 parts by weight of PVP were added. , HPC-120 parts by weight, 8 parts by weight of glycerin, and 10 parts by weight of Macrogol 400 are uniformly mixed or dissolved in 1 part by weight of 1000 parts by weight of ethanol. After spreading and drying, a continuous dissolvable film having a thickness of about 30 μm was formed on the dissolvable film.
以上の腸溶性フィルム、遅発溶解性フィルム、連発溶解
性フィルムにより厚さ約２４０μｍの積層（３ＪＩ）フ
ィルムを形成した。A laminated (3JI) film with a thickness of about 240 μm was formed from the above enteric film, slow dissolving film, and rapid dissolving film.
（実施例９）
腸溶性フィルム（非接着層）：ヒドロキシプロピルメチ
ルセルＯ−スアセテートサクシネート８５重ｆｉ１部、
セラック３重量部をエタノール・塩化メチレン（１：１
）４００重良部に混合溶解させ、また、マク０ゴール４
００１０重置部、酸化チタン２重量部を水１００重量部
に混合溶解又は分散さけ、前記溶液と均一混合し、展延
乾燥後厚さ約１０μｍの腸溶性フィルムを形成した。(Example 9) Enteric film (non-adhesive layer): 1 part of hydroxypropyl methylcell O-suacetate succinate 85 weight fi,
Add 3 parts by weight of shellac to ethanol/methylene chloride (1:1).
) Mixed and dissolved in 400 yen, and also Mac0 Goal 4
0010, 2 parts by weight of titanium oxide was mixed and dissolved or dispersed in 100 parts by weight of water, mixed uniformly with the above solution, and after being spread and dried, an enteric film having a thickness of about 10 μm was formed.
遅発溶解性フィルム（接着性を有する中間層）：塩化リ
ゾデーム１０重沿部、アラントイン５重量部、グリチル
リチン酸ジカリウム５重量部を水１００重間部に均−混
合又は溶解させ、また、ＨＰＣ−Ｈ５０重憬部、ＨＰＣ
−１１０重量部、グリセリン１０重量部、マクロゴール
４００１０重量部をエタノール１０００１００Ｏ部に均
−混合又は溶解させ、前記溶液と均一混合し腸溶性フィ
ルム上に、展延乾燥後厚さ約２００μｍの遅発溶解性フ
ィルムを形成した。Slow-dissolving film (intermediate layer with adhesive properties): 10 parts by weight of Lysodeme chloride, 5 parts by weight of allantoin, and 5 parts by weight of dipotassium glycyrrhizinate are uniformly mixed or dissolved in 100 parts by weight of water, and HPC- H50 Heavyweight Club, HPC
-110 parts by weight, 10 parts by weight of glycerin, and 10 parts by weight of Macrogol were uniformly mixed or dissolved in 1,000,100 parts of ethanol, and the mixture was uniformly mixed with the solution and spread on an enteric film to a thickness of about 200 μm after drying. A soluble film was formed.
連発溶解性フィルム（接着層）：塩化リゾチーム５重聞
部、アラントイン５重量部を水１００重量部に均一に溶
解させ、また、ＨＰＣ−１６０重最重伍プロピレングリ
コール２０重量部、グリセリン１０重量部をエタノール
１０００重量部に均−混合又は溶解させ、前記溶液と均
一混合し、腸溶性フィルム上に展延された遅発溶解性フ
ィルムの上に、展延乾燥後厚さ約３０μｍの連発溶解性
フィルムを形成した。Rapidly soluble film (adhesive layer): 5 parts of lysozyme chloride and 5 parts by weight of allantoin were uniformly dissolved in 100 parts by weight of water, and 20 parts by weight of HPC-160 heavyest propylene glycol and 10 parts by weight of glycerin. was homogeneously mixed or dissolved in 1000 parts by weight of ethanol, mixed uniformly with the solution, and spread on the slow-dissolving film spread on the enteric film to form a continuous dissolving film with a thickness of about 30 μm after drying. A film was formed.
以上、腸溶性フィルム、遅発溶解性フィルム、連発溶解
性フィルムにより厚さ約２４０μｍの積層（３１）フィ
ルムを形成した。As described above, a laminated film (31) having a thickness of about 240 μm was formed using the enteric film, the slow dissolving film, and the rapid dissolving film.
（実施例１０）
腸溶性フィルム（非接＠層）；酢酸フタル酸セルロース
９０重量部、マクロゴール４００１０重量部をエタノー
ル・塩化メチレン（１：１）２００重量部に均一混合し
、展延乾燥後厚さ５μｍの腸溶性フィルムを形成した。(Example 10) Enteric film (non-contact layer): 90 parts by weight of cellulose acetate phthalate and 10 parts by weight of Macrogol 40010 were uniformly mixed with 200 parts by weight of ethanol/methylene chloride (1:1), and after being spread and dried. An enteric film with a thickness of 5 μm was formed.
遅発溶解性フィルム（接着性を有する中間層）；塩化リ
ゾチーム１０重量部、アラントイン５重間部、塩化ナト
リウム５重量部を水１００重量部に溶解させ、また、Ｈ
ＰＣ−８３０重量部、ＮＰＣ−１３０重。Slow-dissolving film (intermediate layer with adhesive properties): 10 parts by weight of lysozyme chloride, 5 parts by weight of allantoin, and 5 parts by weight of sodium chloride were dissolved in 100 parts by weight of water, and
PC-830 parts by weight, NPC-130 parts by weight.
缶部、カルボキシビニルポリマー１０重量部、マクロゴ
ール４００１０重量部をエタノール１０００重Ｍ部に均
−混合又は溶解させ、前記溶液と均一混合し、腸溶性フ
ィルム上に、展延乾燥後厚さ約２５０μｍの遅発溶解性
フィルムを形成した。Can part, 10 parts by weight of carboxyvinyl polymer, and 10 parts by weight of Macrogol 40010 parts by weight were uniformly mixed or dissolved in 1000 parts by weight of ethanol, mixed uniformly with the solution, and spread on an enteric film to a thickness of about 250 μm after drying. A slow dissolving film was formed.
連発溶解性フィルム（接着層）；塩化リゾチーム５明日
部、７ラントイン５重量部、塩化ナトリウム５重量部を
水１０＜１１吊部に溶解させ、また、ＰＶＰ５０重吊部
、重量Ｐｃ−１２５重量部、マクロゴール４００１０重
同郡をエタノール１０００重量部に均一混合または溶解
させ、前記溶液と均一混合し、腸溶性フィルム上に展延
された遅発溶解性フィルムの上に、展延乾燥後厚さ約１
０μｍの連発溶解性 ゛フィルムを形成した。Rapidly soluble film (adhesive layer): 5 parts of lysozyme chloride, 5 parts of 7-lantoin, and 5 parts of sodium chloride were dissolved in 10 < 11 parts of water, and 50 parts of PVP, weight Pc-125 parts by weight. , Macrogol 40010 is uniformly mixed or dissolved in 1000 parts by weight of ethanol, uniformly mixed with the solution, spread on the slow dissolving film spread on the enteric film, and after drying, the thickness is Approximately 1
A continuous dissolving film of 0 μm was formed.
以上の腸溶性フィルム、遅発溶解性フィルム及び連発溶
解性フィルムにより厚さ約２６５μｍの積ｌｉｔ （３
１！ｉ）フィルムを形成した。The product of the above enteric film, slow dissolving film and rapid dissolving film has a thickness of about 265 μm (3
1! i) A film was formed.
以上実施例１乃至１０に述べた２層或いは３層の塩化リ
ゾチーム含有歯肉炎・歯槽膿漏用貼付剤はいずれも歯周
患部に良く密着して広い面積をカバーするので口腔内に
貼付するのに最適であり、違和感を与えず所期の作用効
果を発揮した。All of the two- or three-layer lysozyme chloride-containing patches for gingivitis and alveolar pyorrhea described in Examples 1 to 10 adhere well to the periodontal affected area and cover a wide area, so they can be applied inside the oral cavity. It was ideal for this purpose, and exerted its intended effect without causing any discomfort.
図面は本発明に係る塩化リゾチーム含有歯肉炎・歯槽膿
漏用貼付剤に関するもので第１図、第２図は貼付剤の断
面図、第３図、第４図、第５図、第６図は塩化リゾチー
ムの溶出特性を示すグラフである。
特 許 出 願 人 救急薬品工業株式会社第１図
第２図The drawings relate to the patch for gingivitis and alveolar pyorrhea containing lysozyme chloride according to the present invention, and FIGS. 1 and 2 are cross-sectional views of the patch, and FIGS. 3, 4, 5, and 6. is a graph showing the elution characteristics of lysozyme chloride. Patent applicant: Kyuu Yakuhin Kogyo Co., Ltd. Figure 1 Figure 2
Claims (6)
とを特徴とする塩化リゾチーム含有歯肉炎・歯槽膿漏用
貼付剤。(1) A patch for gingivitis and alveolar pyorrhea containing lysozyme chloride, characterized by containing lysozyme chloride in a water-soluble film.
ール、ハッカ油、酢酸トコフェロール、カミツレチンキ
、塩化セチルピリジニウム、塩酸クロルヘキシジン、ア
ミノ安息香酸エチル、塩酸ジブカイン、塩酸ヘキソチオ
カイン、塩化デカリニウム、グリチルレチン酸、グリチ
ルリチン酸ジカリウム、チモール、塩化ベンザルコニウ
ム、サリチル酸ジフエンヒドラミン、ニトロフラゾン、
テシットデシチン、エデト酸ナトリウム・カルシウム、
フェノール、銅クロロフィリンナトリウム、塩化ナトリ
ウムから選ばれた１種又は２種以上を塩化リゾチームと
ともに含有することを特徴とする塩化リゾチーム含有歯
肉炎・歯槽膿漏用貼付剤。(2) Allantoin, hinokitiol, peppermint oil, tocopherol acetate, chamomile tincture, cetylpyridinium chloride, chlorhexidine hydrochloride, ethyl aminobenzoate, dibucaine hydrochloride, hexothiocaine hydrochloride, dequalinium chloride, glycyrrhetinic acid, dipotassium glycyrrhizinate, Thymol, benzalkonium chloride, diphenhydramine salicylate, nitrofurazone,
tesitdesitin, edetate sodium/calcium,
A patch for gingivitis and alveolar pyorrhea containing lysozyme chloride, characterized in that it contains one or more selected from phenol, sodium copper chlorophyllin, and sodium chloride together with lysozyme chloride.
許請求の範囲第１項又は第２項記載の塩化リゾチーム含
有歯肉炎・歯槽膿漏用貼付剤。(3) The patch for gingivitis and alveolar pyorrhea containing lysozyme chloride according to claim 1 or 2, which contains 0.2 to 20 parts by weight of lysozyme chloride.
チン、ポリビニルアルコール、ポリアクリル酸ナトリウ
ム、カルボキシメチルセルロース、デンプン、キサンタ
ンガム、カラヤガム、アルギン酸ナトリウム、メチルセ
ルロース、カルボキシビニルポリマー、ガンテン、ヒド
ロキシプロピルセルロース、ヒドロキシプロピルメチル
セルロース、アセテートサクシネート、ヒドロキシプロ
ピルメチルセルロースフタレート、酢酸フタル酸セルロ
ース、カルボキシメチルエチルセルロース、及びメタア
クリル酸アクリル酸エチルコポリマーから選ばれた１種
又は２種以上を主成分とする特許請求の範囲第１項乃至
第３項のいずれかに記載の塩化リゾチーム含有歯肉炎・
歯槽膿漏用貼付剤。(4) Water-soluble film contains polyvinylpyrrolidone, gelatin, polyvinyl alcohol, sodium polyacrylate, carboxymethylcellulose, starch, xanthan gum, karaya gum, sodium alginate, methylcellulose, carboxyvinyl polymer, ganten, hydroxypropylcellulose, hydroxypropylmethylcellulose, acetate Claims 1 to 3 are based on one or more selected from succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, carboxymethyl ethyl cellulose, and methacrylic acid ethyl acrylate copolymer. Gingivitis containing lysozyme chloride as described in any of the above
Patch for alveolar pyorrhea.
の範囲第１項乃至第４項のいずれかに記載の塩化リゾチ
ーム含有歯肉炎・歯槽膿漏用貼付剤。(5) The patch for gingivitis and alveolar pyorrhea containing lysozyme chloride according to any one of claims 1 to 4, wherein the water-soluble film is a laminated film.
ｍである特許請求の範囲第１項乃至第５項のいずれかに
記載の塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤。(6) The agent thickness, that is, the thickness of the water-soluble film is 20 to 300μ
The patch for gingivitis and alveolar pyorrhea containing lysozyme chloride according to any one of claims 1 to 5, which is m.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63108053A JPH01279838A (en) | 1988-04-30 | 1988-04-30 | Lysozyme chloride-containing plaster for gingivitis and pyorrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63108053A JPH01279838A (en) | 1988-04-30 | 1988-04-30 | Lysozyme chloride-containing plaster for gingivitis and pyorrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01279838A true JPH01279838A (en) | 1989-11-10 |
| JPH059412B2 JPH059412B2 (en) | 1993-02-04 |
Family
ID=14474723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63108053A Granted JPH01279838A (en) | 1988-04-30 | 1988-04-30 | Lysozyme chloride-containing plaster for gingivitis and pyorrhea |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01279838A (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5578315A (en) * | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
| JP2001505884A (en) * | 1996-12-16 | 2001-05-08 | エルティエス ローマン テラピー−ズュステーメ アーゲー | Active substance-containing and especially fragrance-containing film dosage forms that can be dosed individually and break down rapidly on contact with liquids |
| JP2003514009A (en) * | 1999-11-12 | 2003-04-15 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Thin-film formulations for two-phase release of pharmacologically active substances or other substances |
| WO2005120455A1 (en) * | 2004-06-12 | 2005-12-22 | Passion For Life Healthcare Limited | Soluble strip for oral or topical administration |
| JP2006510611A (en) * | 2002-11-13 | 2006-03-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Multi-layer transmucosal treatment system |
| JP2006117600A (en) * | 2004-10-22 | 2006-05-11 | Nippon Zettoc Co Ltd | Cleaning agent for material to be attached to oral cavity and surface-treating agent for material to be attached to oral cavity |
| JP2007326808A (en) * | 2006-06-07 | 2007-12-20 | Matsutani Chem Ind Ltd | Edible film for oral hygiene |
| USRE42126E1 (en) | 1999-07-02 | 2011-02-08 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
| JP2012533522A (en) * | 2009-07-17 | 2012-12-27 | クロクス テクノロジーズ インコーポレイテッド | Combination of oxidizing agents, photosensitizers and wound healing agents for oral disinfection and treatment of oral diseases |
| US8986719B2 (en) | 2005-11-09 | 2015-03-24 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| US9345648B2 (en) | 2006-11-09 | 2016-05-24 | Klox Technologies Inc. | Photoactivatable oxygen-evolving compositions and methods for teeth whitening |
| US9375446B2 (en) | 2008-11-07 | 2016-06-28 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| US9554976B2 (en) | 2002-09-11 | 2017-01-31 | The Procter & Gamble Company | Tooth whitening product |
| US9655829B2 (en) | 2012-09-14 | 2017-05-23 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
| CN107106512A (en) * | 2015-11-25 | 2017-08-29 | 缇碧艾姆株式会社 | Stop blooding and Wound protection film in oral cavity |
| US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
| US10285916B2 (en) | 2012-10-17 | 2019-05-14 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
| US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
| US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
| US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5290638A (en) * | 1976-01-27 | 1977-07-30 | Sunstar Inc | Lysozymeeblended dentifrice compound |
| JPS61280423A (en) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
| JPS62135417A (en) * | 1985-12-09 | 1987-06-18 | Sato Seiyaku Kk | Filmy pharmaceutical |
| JPS62255417A (en) * | 1986-04-25 | 1987-11-07 | Sunstar Inc | Pharmaceutical preparation for oral cavity |
-
1988
- 1988-04-30 JP JP63108053A patent/JPH01279838A/en active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5290638A (en) * | 1976-01-27 | 1977-07-30 | Sunstar Inc | Lysozymeeblended dentifrice compound |
| JPS61280423A (en) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
| JPS62135417A (en) * | 1985-12-09 | 1987-06-18 | Sato Seiyaku Kk | Filmy pharmaceutical |
| JPS62255417A (en) * | 1986-04-25 | 1987-11-07 | Sunstar Inc | Pharmaceutical preparation for oral cavity |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314915A (en) * | 1991-09-25 | 1994-05-24 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5462749A (en) * | 1991-09-25 | 1995-10-31 | Mcnell-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5578315A (en) * | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
| JP2001505884A (en) * | 1996-12-16 | 2001-05-08 | エルティエス ローマン テラピー−ズュステーメ アーゲー | Active substance-containing and especially fragrance-containing film dosage forms that can be dosed individually and break down rapidly on contact with liquids |
| USRE42126E1 (en) | 1999-07-02 | 2011-02-08 | The Procter & Gamble Company | Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip |
| JP4825385B2 (en) * | 1999-11-12 | 2011-11-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Thin film formulation for two-phase release of pharmacologically active substances or other substances |
| JP2003514009A (en) * | 1999-11-12 | 2003-04-15 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Thin-film formulations for two-phase release of pharmacologically active substances or other substances |
| US9554976B2 (en) | 2002-09-11 | 2017-01-31 | The Procter & Gamble Company | Tooth whitening product |
| US10493016B2 (en) | 2002-09-11 | 2019-12-03 | The Procter & Gamble Company | Tooth whitening product |
| JP2006510611A (en) * | 2002-11-13 | 2006-03-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Multi-layer transmucosal treatment system |
| JP4653488B2 (en) * | 2002-11-13 | 2011-03-16 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Multi-layer transmucosal treatment system |
| WO2005120455A1 (en) * | 2004-06-12 | 2005-12-22 | Passion For Life Healthcare Limited | Soluble strip for oral or topical administration |
| JP2006117600A (en) * | 2004-10-22 | 2006-05-11 | Nippon Zettoc Co Ltd | Cleaning agent for material to be attached to oral cavity and surface-treating agent for material to be attached to oral cavity |
| US8986719B2 (en) | 2005-11-09 | 2015-03-24 | Klox Technologies Inc. | Teeth whitening compositions and methods |
| JP2007326808A (en) * | 2006-06-07 | 2007-12-20 | Matsutani Chem Ind Ltd | Edible film for oral hygiene |
| US9345648B2 (en) | 2006-11-09 | 2016-05-24 | Klox Technologies Inc. | Photoactivatable oxygen-evolving compositions and methods for teeth whitening |
| US10485986B2 (en) | 2008-11-07 | 2019-11-26 | Klox Technologies Inc. | Methods and compositions for treatment of pigmented lesions |
| US10149985B2 (en) | 2008-11-07 | 2018-12-11 | Klox Technologies Inc. | Methods and compositions for treating rosacea |
| US11691025B2 (en) | 2008-11-07 | 2023-07-04 | Klox Technologies Inc. | Methods and compositions for reversing or mitigating skin aging |
| US11020609B2 (en) | 2008-11-07 | 2021-06-01 | Klox Technologies Inc. | Methods and compositions for treatment of pigmented lesions |
| US9375446B2 (en) | 2008-11-07 | 2016-06-28 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| US10322179B2 (en) | 2009-07-17 | 2019-06-18 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US10471147B2 (en) | 2009-07-17 | 2019-11-12 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US9603929B2 (en) | 2009-07-17 | 2017-03-28 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfecton and treatment of oral disease |
| US11141482B2 (en) | 2009-07-17 | 2021-10-12 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| JP2012533522A (en) * | 2009-07-17 | 2012-12-27 | クロクス テクノロジーズ インコーポレイテッド | Combination of oxidizing agents, photosensitizers and wound healing agents for oral disinfection and treatment of oral diseases |
| US8986746B2 (en) | 2009-07-17 | 2015-03-24 | Klox Technologies Inc. | Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease |
| US11116841B2 (en) | 2012-04-20 | 2021-09-14 | Klox Technologies Inc. | Biophotonic compositions, kits and methods |
| US10213373B2 (en) | 2012-04-20 | 2019-02-26 | Klox Technologies, Inc. | Chromophore combinations for biophotonic uses |
| US9655829B2 (en) | 2012-09-14 | 2017-05-23 | Valeant Pharmaceuticals International, Inc. | Compositions and methods for teeth whitening |
| US10285916B2 (en) | 2012-10-17 | 2019-05-14 | The Procter & Gamble Company | Strip for the delivery of an oral care active and methods for applying oral care actives |
| US10130706B2 (en) | 2013-03-14 | 2018-11-20 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US11324823B2 (en) | 2013-03-14 | 2022-05-10 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
| US10881736B2 (en) | 2013-07-03 | 2021-01-05 | Klox Technologies Inc. | Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds |
| US10772990B2 (en) | 2014-04-01 | 2020-09-15 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US10207029B2 (en) | 2014-04-01 | 2019-02-19 | Klox Technologies Inc. | Tissue filler compositions and methods of use |
| US11421349B2 (en) | 2014-10-31 | 2022-08-23 | Klox Technologies Inc. | Photoactivatable fibers and fabric media |
| CN107106512A (en) * | 2015-11-25 | 2017-08-29 | 缇碧艾姆株式会社 | Stop blooding and Wound protection film in oral cavity |
| JP2018538233A (en) * | 2015-11-25 | 2018-12-27 | ティービーエム カンパニーＴｂｍ Ｃｏｍｐａｎｙ | Oral hemostasis and wound protection film |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH059412B2 (en) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH01279838A (en) | Lysozyme chloride-containing plaster for gingivitis and pyorrhea | |
| JP6770157B2 (en) | A composition containing electrohydrodynamically obtained fibers for administering a specific dosage of the active substance to the skin or mucous membranes. | |
| US5160737A (en) | Liquid polymer composition, and method of use | |
| US4307075A (en) | Topical treatment of aphthous stomatitis | |
| JP6929916B2 (en) | An electrohydrodynamically obtained pharmaceutical composition containing fibers with improved residence time at the application site. | |
| KR101901660B1 (en) | Bandage for Oral hemostasis and wound protection | |
| JPS63160649A (en) | Base material adhered to oral cavity | |
| RU2450819C2 (en) | Herbal compositions for treating oral diseases | |
| JP5590891B2 (en) | Edible film | |
| JP2005504763A (en) | Mucoadhesive corrosive drug delivery device for controlled administration of pharmaceuticals and other active compounds | |
| Mizrahi et al. | Mucoadhesive polymers for delivery of drugs to the oral cavity | |
| KR20060135052A (en) | Preparation for oral administration | |
| TW200538280A (en) | Film compositions | |
| AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| JP4597273B2 (en) | Oral composition | |
| K Maurya et al. | Therapeutic potential of mucoadhesive drug delivery systems-An updated patent review | |
| JPS58213709A (en) | Application agent for gum mucosa | |
| JPWO2009041111A1 (en) | Oral administration | |
| JPH05246845A (en) | Antipyretic analgesic agent containing ibuprofen | |
| WO2015101907A1 (en) | Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels | |
| AU2022351983A1 (en) | Composition and method for prevention and treatment of cutaneous radiation injury | |
| Bhandari et al. | REVIEW ON MUCOADHESIVE BUCCAL DRUG DELIVERY. | |
| Pattnaik et al. | Periodontal muco-adhesive formulations for the treatment of infectious periodontal diseases | |
| KR20220055901A (en) | Wound covering material for oral wound protection and self-treatment using adhesive polymer | |
| JPH01230514A (en) | Aerosol type patch external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |